Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products

AAPS Journal

Volumn 17, Issue 3, 2015, Pages 758-768

  Hendeles, Leslie ^a   Daley Yates, Peter T ^b   Hermann, Robert ^c   De Backer, Jan ^d   Dissanayake, Sanjeeva ^e   Horhota, Stephen T ^f  

^a UNIVERSITY OF FLORIDA   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Clinical Research Appliance   (Germany)

^d FLUIDDA NV   (Belgium)

^e Mundipharma Research Ltd   (United Kingdom)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

inhaled bronchodilators; inhaled corticosteroids; methacholine; pharmacodynamics

Indexed keywords

BRONCHODILATING AGENT; GLUCOCORTICOID;

HUMAN; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; THERAPEUTIC EQUIVALENCE;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; GLUCOCORTICOIDS; HUMANS; RESEARCH DESIGN; THERAPEUTIC EQUIVALENCY;

EID: 84939564601     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9735-7     Document Type: Article

References (37)

1. Daley-Yates P. Biomarkers of the anti-inflammatory effects in the airways and the evaluation of therapeutic equivalence. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx. Accessed 13 Nov 2014.
2. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–15.
3. Daley-Yates PT, Austin DJ, Bentley JH. Exhaled nitric oxide (eNO) versus adenosine-5′-monophosphate (AMP) challenge for demonstrating dose response to inhaled corticosteroid (abstract). Am J Respir Crit Care Med. 2013;187:A1926.
4. Singh D, Fairwood J, Murdoch R, Weeks A, Russell P, Roy K, et al. The reproducibility of adenosine monophosphate bronchial challenges in mind, steroid-naive asthmatics. Br J Clin Pharmacol. 2008;66:261–5.
5. Austin DJ, Daley-Yates PT. Evaluation of exhaled nitric oxide (eNO) as a tool for bioequivalence testing of inhaled corticosteroids (abstract). Am J Respir Crit Care Med. 2013;187:A1927.
6. Kandala B. Evaluation of the feasibility of pharmacodynamic BE studies of OIDPs through Monte Carlo simulations. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx. Accessed 13 Nov 2014.
7. Weiler JM, Sorkness CA, Hendeles L, Zhu Y, Nichols S. Exploration of exhaled nitric oxide (eNO) levels following treatment with fluticasone propionate (FP)/salmeterol xinafoate (SX) combination inhaled product to demonstrate pharmacodynamic (PD) FP bioequivalence (BE). ClinicalTrials.gov NCT 00927758. Accessed 25 Nov 2014.
8. Hermann R. Points to consider in the design and conduct of HPA-axis studies comparing the systemic safety of ICS-products. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx. Accessed 13 Nov 2014.
9. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. CPMP/EWP/4151/00 Rev. 1; 22 January 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003504.pdf. Accessed 22 Oct 2014.
10. Food and Drug Administration. Draft guidance on fluticasone propionate; salmeterol xinafoate. Recommended September 2013. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm367643.pdf. Accessed 21 Oct 2014.
11. WHO-Five Well-being Index (WHO-5). Psychiatric Research Unit, Mental Health Central North Zealand, Hillerød, Denmark. 2014. http://www.who-5.org. Accessed 21 Oct 2014.
12. Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP, Grobbee DE, et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab. 1998;83:47–54.
13. van Rossum EF, Lamberts SW. Glucocorticoid resistance syndrome: a diagnostic and therapeutic approach. Best Pract Res Clin Endocrinol Metab. 2006;20:611–26.
14. Selmaoui B, Touitou Y. Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sci. 2003;73:3339–49.
15. Hendeles L. Use of bronchoprovocation to determine bioequivalence of beta agonists. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx. Accessed 13 Nov 2014.
16. Ahrens RC, Harris JB, Milavetz G, Annis L, Ries R. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. J Allergy Clin Immunol. 1987;79:876–82.
17. Ahrens RC, Hendeles L, Clarke WR, Dockhorn RJ, Hill MR, Vaughan LM, et al. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine. Am J Respir Crit Care Med. 1999;160:1238–43.
18. Parameswaran KN, Inman MD, Ekholm BP, Morris MM, Summers E, O’Byrne PM, et al. Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. Am J Respir Crit Care Med. 1999;160:354–7.
19. 2-adrenergic agonist. Pharmacotherapy. 2011;31:449–57.
20. Hendeles L, Ahrens R, Sorkness C, Nguyen DT, Maus J, Dakovic R. Relative potency of formoterol Novolizer® 12 μg compared to formoterol Aerolizer® 12 μg in patients with stable asthma using bronchoprovocation with methacholine as a bioassay. Clinicaltrials.gov identifier: NCT01256086. Accessed 17 Jul 2014.
21. Darken P. Handling reference product variability in PK/PD trials. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx. Accessed 13 Nov 2014.
22. Haughie S. Some statistical considerations in the design and analysis of equivalence studies using pharmacodynamic and clinical endpoints. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx. Accessed 13 Nov 2014.
23. Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 1999;160:244–9.
24. Derom EY, Pauwels RA, Van der Straeten ME. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J Allergy Clin Immunol. 1992;89:811–5.
25. Higham MA, Sharara AM, Wilson P, Jenkins RJ, Glendenning GA, Ind PW. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma. Thorax. 1997;52:975–80.
26. Food and Drug Administration. Draft Guidance on Albuterol Sulfate. Recommended April 2013, Revised June 2013. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm346985.pdf. Accessed 22 Oct 2014.
27. Horhota S. IVIV OIP BE Case Study: PK and PD tiotropium in COPD HandiHaler 2. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx. Accessed 13 Nov 2014.
28. 2-agonist metered dose inhaler. 1999. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/inhal-aerosol/mdi_bad-eng.php. Accessed 24 Oct 2014.
29. Bennett JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax. 1997;52:458–64.
30. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose–response comparison in healthy subjects. Thorax. 2000;55:650–6.
31. Kempsford R, Handel M, Mehta R, De Silva M, Daley-Yates P. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. Respir Med. 2005;99 Suppl 1:S11–19.
32. Clearie KL, Williamson PA, Vaidyanathan S, Du Bois J, Nell H, Lipworth BJ. Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in health volunteers via pMDI alone and spacer. Br J Clin Pharmacol. 2010;69:637–44.
33. Pauwels R, Newman S, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J. 1997;10:2127–38.
34. Stewart BA, Ahrens RC, Carrier S, Frosolono M, Lux C, Han SH, et al. Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. Chest. 2000;117:714–21.
35. De Backer J. A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx. Accessed 13 Nov 2014.
36. De Backer W, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Hufkens A, et al. The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients. Eur Respir J. 2014;44:527–9.
37. Janssens W, Liu Y, Liu D, Kesten S, Tashkin DP, Celli BR, et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®). Respir Med. 2013;107:1409–16.